First launched in 2005, pharmaREADY is a fully integrated, regulatory compliant, web-based platform to create, view, and manage global regulatory submissions
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
Takeda is establishing the capability to manufacture TAK-019 (known outside Japan as NVX-CoV2373) at its facilities in Japan and aims to begin distribution in the early calendar year 2022
It adds Rezurock (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD)
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Subscribe To Our Newsletter & Stay Updated
